A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

Trial Profile

A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Bupivacaine (Primary) ; Bupivacaine/meloxicam (Primary) ; Bupivacaine/meloxicam (Primary) ; Meloxicam (Primary)
  • Indications Perioperative pain
  • Focus Therapeutic Use
  • Sponsors Heron Therapeutics
  • Most Recent Events

    • 31 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Dec 2016 This trial is now studying Bupivacaine and meloxicam alone along with combination of the same. Thus changes in official title, purpose and treatment.
    • 29 Dec 2016 Planned number of patients changed from 333 to 398.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top